Pancreatic duct stent preventing post endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients
10.3724/SP.J.1008.2015.01319
- Author:
Lu WEI
1
Author Information
1. Department of Gastroenterology, The Second Affiliated Hospital of Nanjing Medical University
- Publication Type:Journal Article
- Keywords:
Endoscopic retrograde cholangiopancreatography;
Hyperamylasemia and high-risk patients;
Pancreatic duct stent;
Pancreatitis
- From:
Academic Journal of Second Military Medical University
2015;36(12):1319-1323
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the preventive effect of pancreatic duct stent against post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) and hyperamylasemia in high-risk patients. Methods A total of 160 patients with high-risk PEP underwent ERCP therapy between Jan. 2013 and Dec. 2014 and were retrospectively analyzed. The patients were divided into pancreatic duct stent group (n =82) and-control group (n=78) according to whether receiving pancreatic duct stent or not. Abdominal pain was evaluated after ERCP. The levels of serum amylase were detected at 3 h and 24 h after ERCP. The incidences of PEP and hyperamylasemia were compared between the two groups. Results The serum amylase levels at 3 h and 24 h after ERCP in pancreatic duct stent group were significantly lower than those in control group ([184. 89±257. 33] U/L vs [305. 35±371. 81] U/L, P<0. 05; [268. 07±344. 73] U/L vs [465. 86±639. 94] U/L, P< 0. 05). The incidences of PEP and hyperamylasemia in pancreatic duct stent group were also significantly lower than those in control group (2. 4% [2/82] vs 11. 5% [9/78], P<0. 05; 17. 1% [14/82] vs 30. 8% [24/78], P<0. 05). The incidence of abdominal pain and abdominal pain score were (19. 5% [16/82], [1. 24 + 0. 58]) in pancreatic duct stent group, which were significantly lower than those in control group (43. 6% [34/78], [1. 68±0. 97]) (P = 0. 001). Conclusion Pancreatic duct stent can effectively prevent PEP and hyperamylasemia in high-risk patients following ERCP.
